HTLV-1 Tax-Mediated Inhibition of FOXO3a Activity Is Critical for the Persistence of Terminally Differentiated CD4 T Cells

English version České info

HTLV- infection contributes to the development of Adult T cell Leukemia (ATL) or the neurological disorder HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HTLV-1 principally targets CD4+ T lymphocytes and causes profound changes in activation, immune function and cell death. The molecular mechanisms involved in the persistence of infected CD4+ T cells following primary HTLV-1 infection remain unclear. We demonstrate here that the Tax oncoprotein inactivates the FOXO3a transcription factor to facilitate the long-term survival of a population of highly activated and terminally differentiated T cells that maintain the capacity to spread infectious viral particles. Mechanistically, expression of Tax oncoprotein in primary human CD4+ T cells resulted in the phosphorylation-dependent inactivation of FOXO3a, via the AKT kinase. Tax-mediated CD4+ T cell persistence was also reversed by chemical inhibition of the AKT pathway, and reproduced by the expression of a dominant negative version of FOXO3a itself or by silencing its transcriptionally active form using specific siRNA. Overall this study provides new mechanistic insights used by Tax to potentiate the long-term maintenance of CD4+ T lymphocytes following HTLV-1 infection and suggests that modulation of FOXO3a activity, using a range of inhibitors targeting the PI3K-AKT-FOXO3a pathway, may offer a valuable addition to current therapeutic approaches.

Vyšlo v časopise: HTLV-1 Tax-Mediated Inhibition of FOXO3a Activity Is Critical for the Persistence of Terminally Differentiated CD4 T Cells. PLoS Pathog 10(12): e32767. doi:10.1371/journal.ppat.1004575
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004575

Souhrn

Zdroje

1. CookLB, ElemansM, RowanAG, AsquithB (2013) HTLV-1: persistence and pathogenesis. Virology 435: 131–140.

2. VerdonckK, GonzalezE, Van DoorenS, VandammeAM, VanhamG, et al. (2007) Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 7: 266–281.

3. JonesKS, Petrow-SadowskiC, HuangYK, BertoletteDC, RuscettiFW (2008) Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med 14: 429–436.

4. SzeA, BelgnaouiSM, OlagnierD, LinR, HiscottJ, et al. (2013) Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis. Cell Host Microbe 14: 422–434.

5. RatnerL (2004) Adult T cell leukemia lymphoma. Front Biosci 9: 2852–2859.

6. YasunagaJ, MatsuokaM (2007) Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms. Cancer Control 14: 133–140.

7. CharoenthongtrakulS, ZhouQ, ShembadeN, HarhajNS, HarhajEW (2011) Human T cell leukemia virus type 1 Tax inhibits innate antiviral signaling via NF-kappaB-dependent induction of SOCS1. J Virol 85: 6955–6962.

8. MatsuokaM, JeangKT (2007) Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 7: 270–280.

9. PeloponeseJMJr, JeangKT (2006) Role for Akt/protein kinase B and activator protein-1 in cellular proliferation induced by the human T-cell leukemia virus type 1 tax oncoprotein. J Biol Chem 281: 8927–8938.

10. ShembadeN, HarhajNS, YamamotoM, AkiraS, HarhajEW (2007) The human T-cell leukemia virus type 1 Tax oncoprotein requires the ubiquitin-conjugating enzyme Ubc13 for NF-kappaB activation. J Virol 81: 13735–13742.

11. OteizaA, MechtiN (2011) The human T-cell leukemia virus type 1 oncoprotein tax controls forkhead box O4 activity through degradation by the proteasome. J Virol 85: 6480–6491.

12. ShembadeN, HarhajEW (2011) Outfoxing FoxO transcription factors: HTLV-1 Tax oncoprotein inactivates FoxO4 via the ubiquitin-proteasome pathway. Future Virol 6: 1165–1168.

13. Tanaka-NakanishiA, YasunagaJ, TakaiK, MatsuokaM (2014) HTLV-1 bZIP factor suppresses apoptosis by attenuating the function of FoxO3a and altering its localization. Cancer Res 74: 188–200.

14. van GrevenyngheJ, CubasRA, DaFonsecaS, MetcalfT, TremblayCL, et al. (2012) Foxo3a: an integrator of immune dysfunction during HIV infection. Cytokine Growth Factor Rev 23: 215–221.

15. van GrevenyngheJ, ProcopioFA, HeZ, ChomontN, RiouC, et al. (2008) Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat Med 14: 266–274.

16. LeeJC, EspeliM, AndersonCA, LintermanMA, PocockJM, et al. (2013) Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 155: 57–69.

17. MonsalveM, OlmosY (2011) The complex biology of FOXO. Curr Drug Targets 12: 1322–1350.

18. YangJY, HungMC (2011) Deciphering the role of forkhead transcription factors in cancer therapy. Curr Drug Targets 12: 1284–1290.

19. FuziiHT, da Silva DiasGA, de BarrosRJ, FalcaoLF, QuaresmaJA (2014) Immunopathogenesis of HTLV-1-assoaciated myelopathy/tropical spastic paraparesis (HAM/TSP). Life Sci 104: 9–14.

20. RomanelliMG, DianiE, BergamoE, CasoliC, CiminaleV, et al. (2013) Highlights on distinctive structural and functional properties of HTLV Tax proteins. Front Microbiol 4: 271.

21. HuangH, TindallDJ (2007) Dynamic FoxO transcription factors. J Cell Sci 120: 2479–2487.

22. van den BergMC, van GoghIJ, SmitsAM, van TriestM, DansenTB, et al. (2013) The small GTPase RALA controls c-Jun N-terminal kinase-mediated FOXO activation by regulation of a JIP1 scaffold complex. J Biol Chem 288: 21729–21741.

23. RiouC, Yassine-DiabB, Van grevenyngheJ, SomogyiR, GrellerLD, et al. (2007) Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells. J Exp Med 204: 79–91.

24. DabrowskaA, KimN, AldoviniA (2008) Tat-induced FOXO3a is a key mediator of apoptosis in HIV-1-infected human CD4+ T lymphocytes. J Immunol 181: 8460–8477.

25. KimN, KukkonenS, GuptaS, AldoviniA (2010) Association of Tat with promoters of PTEN and PP2A subunits is key to transcriptional activation of apoptotic pathways in HIV-infected CD4+ T cells. PLoS Pathog 6: e1001103.

26. JonesKS, Petrow-SadowskiC, BertoletteDC, HuangY, RuscettiFW (2005) Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells. J Virol 79: 12692–12702.

27. FritschRD, ShenX, SimsGP, HathcockKS, HodesRJ, et al. (2005) Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J Immunol 175: 6489–6497.

28. MaCS, HodgkinPD, TangyeSG (2004) Automatic generation of lymphocyte heterogeneity: Division-dependent changes in the expression of CD27, CCR7 and CD45 by activated human naive CD4+ T cells are independently regulated. Immunol Cell Biol 82: 67–74.

29. WilsonMK, McWhirterSM, AminRH, HuangD, SchlisselMS (2010) Abelson virus transformation prevents TRAIL expression by inhibiting FoxO3a and NF-kappaB. Mol Cells 29: 333–341.

30. BellonM, BaydounHH, YaoY, NicotC (2010) HTLV-I Tax-dependent and -independent events associated with immortalization of human primary T lymphocytes. Blood 115: 2441–2448.

31. BoxusM, TwizereJC, LegrosS, DewulfJF, KettmannR, et al. (2008) The HTLV-1 Tax interactome. Retrovirology 5: 76.

32. SaitoK, SaitoM, TaniuraN, OkuwaT, OharaY (2010) Activation of the PI3K-Akt pathway by human T cell leukemia virus type 1 (HTLV-1) oncoprotein Tax increases Bcl3 expression, which is associated with enhanced growth of HTLV-1-infected T cells. Virology 403: 173–180.

33. HiscottJ, NguyenTL, ArguelloM, NakhaeiP, PazS (2006) Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. Oncogene 25: 6844–6867.

34. OliereS, HernandezE, LezinA, ArguelloM, DouvilleR, et al. (2010) HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1). PLoS Pathog 6: e1001177.

35. TwizereJC, SpringaelJY, BoxusM, BurnyA, DequiedtF, et al. (2007) Human T-cell leukemia virus type-1 Tax oncoprotein regulates G-protein signaling. Blood 109: 1051–1060.

36. CharvetC, AlbertiI, LucianoF, JacquelA, BernardA, et al. (2003) Proteolytic regulation of Forkhead transcription factor FOXO3a by caspase-3-like proteases. Oncogene 22: 4557–4568.

37. KashanchiF, BradyJN (2005) Transcriptional and post-transcriptional gene regulation of HTLV-1. Oncogene 24: 5938–5951.

38. OliereS, DouvilleR, SzeA, BelgnaouiSM, HiscottJ (2011) Modulation of innate immune responses during human T-cell leukemia virus (HTLV-1) pathogenesis. Cytokine Growth Factor Rev 22: 197–210.

39. CalnanDR, BrunetA (2008) The FoxO code. Oncogene 27: 2276–2288.

40. HironakaN, MochidaK, MoriN, MaedaM, YamamotoN, et al. (2004) Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells. Neoplasia 6: 266–278.

41. NakahataS, IchikawaT, ManeesaayP, SaitoY, NagaiK, et al. (2014) Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers. Nat Commun 5: 3393.

42. SaitoM, MatsuzakiT, SatouY, YasunagaJ, SaitoK, et al. (2009) In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology 6: 19.

43. LiM, KesicM, YinH, YuL, GreenPL (2009) Kinetic analysis of human T-cell leukemia virus type 1 gene expression in cell culture and infected animals. J Virol 83: 3788–3797.

44. van GrevenyngheJ, CubasRA, NotoA, DaFonsecaS, HeZ, et al. (2011) Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. J Clin Invest 121: 3877–3888.

45. van GrevenyngheJ, HalwaniR, ChomontN, AncutaP, PeretzY, et al. (2008) Lymph node architecture collapse and consequent modulation of FOXO3a pathway on memory T- and B-cells during HIV infection. Semin Immunol 20: 196–203.

46. KinoT, De MartinoMU, CharmandariE, IchijoT, OutasT, et al. (2005) HIV-1 accessory protein Vpr inhibits the effect of insulin on the Foxo subfamily of forkhead transcription factors by interfering with their binding to 14-3-3 proteins: potential clinical implications regarding the insulin resistance of HIV-1-infected patients. Diabetes 54: 23–31.

47. CuiM, HuangY, ZhaoY, ZhengJ (2008) Transcription factor FOXO3a mediates apoptosis in HIV-1-infected macrophages. J Immunol 180: 898–906.

48. GoncalvesDU, ProiettiFA, Barbosa-StancioliEF, MartinsML, RibasJG, et al. (2008) HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) inflammatory network. Inflamm Allergy Drug Targets 7: 98–107.

49. TattermuschS, SkinnerJA, ChaussabelD, BanchereauJ, BerryMP, et al. (2012) Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy. PLoS Pathog 8: e1002480.

50. FukushimaN, NishiuraY, NakamuraT, KohnoS, EguchiK (2007) Blockade of IL-2 receptor suppresses HTLV-I and IFN-gamma expression in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Intern Med 46: 347–351.

51. MarcaisA, SuarezF, SibonD, BazarbachiA, HermineO (2012) Clinical trials of adult T-cell leukaemia/lymphoma treatment. Leuk Res Treatment 2012: 932175.

52. MarcaisA, SuarezF, SibonD, FrenzelL, HermineO, et al. (2013) Therapeutic options for adult T-cell leukemia/lymphoma. Curr Oncol Rep 15: 457–464.

53. WhiteY, YoshimitsuM, KozakoT, MatsushitaK, KoriyamaC, et al. (2013) Effects of exogenous interleukin-7 on CD8(+) T-cell survival and function in human T-cell lymphotropic virus type 1 infection. Leuk Lymphoma 54: 2243–2250.

54. PalSK, ReckampK, YuH, FiglinRA (2010) Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 19: 1355–1366.